The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration

X. M. Gao, T. Hashimoto, T. B. Cooper, C. A. Tamminga

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Whether the pathophysiology and treatment of neuroleptic-induced oral dyskinesias in rats parallel that for tardive dyskinesia in humans remains a question. To address the issue further, Sprague Dawley rats were treated for 6 months with multiple oral doses of haloperidol (1.5 and 3.0 mg/kg/day) or clozapine (10, 20, and 30 mg/kg/day) and compared with water treated animals. The rate of oral dyskinesias was monitored at study start and monthly by trained raters who were blind to treatment. group. All haloperidol-treated rats developed oral dyskinesias at a significantly higher rate than rats treated with water (p = 0.0007) or those treated with clozapine (p = 0.0017). Each dose of haloperidol produced significantly higher rates of oral dyskinesias than did any dose of clozapine and did so in an apparent dose-sensitive manner. Clozapine lacked a dose-sensitive relationship with the oral dyskinesias, and failed to show a significant difference in rate from control rats at any dose. Plasma levels of haloperidol with these doses were in the human therapeutic range; with clozapine only the highest dose produced plasma levels in the human therapeutic range. These data show little association between rat oral dyskinesias and clozapine treatment, whereas a strong association is present with haloperidol. The data are, thereby, consistent with the clinical association of tardive dyskinesia with typical neuroleptics like haloperidol but not with the atypical neuroleptic clozapine.

Original languageEnglish (US)
Pages (from-to)97-104
Number of pages8
JournalJournal of Neural Transmission
Volume104
Issue number1
DOIs
StatePublished - 1997

Fingerprint

Clozapine
Movement Disorders
Haloperidol
Antipsychotic Agents
Water
Sprague Dawley Rats
Therapeutics

Keywords

  • Chronic clozapine
  • Chronic haloperidol
  • Dose-response
  • Oral dyskinesias
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration. / Gao, X. M.; Hashimoto, T.; Cooper, T. B.; Tamminga, C. A.

In: Journal of Neural Transmission, Vol. 104, No. 1, 1997, p. 97-104.

Research output: Contribution to journalArticle

@article{1acf836bedc347c39cdaba8ecbefc56e,
title = "The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration",
abstract = "Whether the pathophysiology and treatment of neuroleptic-induced oral dyskinesias in rats parallel that for tardive dyskinesia in humans remains a question. To address the issue further, Sprague Dawley rats were treated for 6 months with multiple oral doses of haloperidol (1.5 and 3.0 mg/kg/day) or clozapine (10, 20, and 30 mg/kg/day) and compared with water treated animals. The rate of oral dyskinesias was monitored at study start and monthly by trained raters who were blind to treatment. group. All haloperidol-treated rats developed oral dyskinesias at a significantly higher rate than rats treated with water (p = 0.0007) or those treated with clozapine (p = 0.0017). Each dose of haloperidol produced significantly higher rates of oral dyskinesias than did any dose of clozapine and did so in an apparent dose-sensitive manner. Clozapine lacked a dose-sensitive relationship with the oral dyskinesias, and failed to show a significant difference in rate from control rats at any dose. Plasma levels of haloperidol with these doses were in the human therapeutic range; with clozapine only the highest dose produced plasma levels in the human therapeutic range. These data show little association between rat oral dyskinesias and clozapine treatment, whereas a strong association is present with haloperidol. The data are, thereby, consistent with the clinical association of tardive dyskinesia with typical neuroleptics like haloperidol but not with the atypical neuroleptic clozapine.",
keywords = "Chronic clozapine, Chronic haloperidol, Dose-response, Oral dyskinesias, Tardive dyskinesia",
author = "Gao, {X. M.} and T. Hashimoto and Cooper, {T. B.} and Tamminga, {C. A.}",
year = "1997",
doi = "10.1007/BF01271298",
language = "English (US)",
volume = "104",
pages = "97--104",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration

AU - Gao, X. M.

AU - Hashimoto, T.

AU - Cooper, T. B.

AU - Tamminga, C. A.

PY - 1997

Y1 - 1997

N2 - Whether the pathophysiology and treatment of neuroleptic-induced oral dyskinesias in rats parallel that for tardive dyskinesia in humans remains a question. To address the issue further, Sprague Dawley rats were treated for 6 months with multiple oral doses of haloperidol (1.5 and 3.0 mg/kg/day) or clozapine (10, 20, and 30 mg/kg/day) and compared with water treated animals. The rate of oral dyskinesias was monitored at study start and monthly by trained raters who were blind to treatment. group. All haloperidol-treated rats developed oral dyskinesias at a significantly higher rate than rats treated with water (p = 0.0007) or those treated with clozapine (p = 0.0017). Each dose of haloperidol produced significantly higher rates of oral dyskinesias than did any dose of clozapine and did so in an apparent dose-sensitive manner. Clozapine lacked a dose-sensitive relationship with the oral dyskinesias, and failed to show a significant difference in rate from control rats at any dose. Plasma levels of haloperidol with these doses were in the human therapeutic range; with clozapine only the highest dose produced plasma levels in the human therapeutic range. These data show little association between rat oral dyskinesias and clozapine treatment, whereas a strong association is present with haloperidol. The data are, thereby, consistent with the clinical association of tardive dyskinesia with typical neuroleptics like haloperidol but not with the atypical neuroleptic clozapine.

AB - Whether the pathophysiology and treatment of neuroleptic-induced oral dyskinesias in rats parallel that for tardive dyskinesia in humans remains a question. To address the issue further, Sprague Dawley rats were treated for 6 months with multiple oral doses of haloperidol (1.5 and 3.0 mg/kg/day) or clozapine (10, 20, and 30 mg/kg/day) and compared with water treated animals. The rate of oral dyskinesias was monitored at study start and monthly by trained raters who were blind to treatment. group. All haloperidol-treated rats developed oral dyskinesias at a significantly higher rate than rats treated with water (p = 0.0007) or those treated with clozapine (p = 0.0017). Each dose of haloperidol produced significantly higher rates of oral dyskinesias than did any dose of clozapine and did so in an apparent dose-sensitive manner. Clozapine lacked a dose-sensitive relationship with the oral dyskinesias, and failed to show a significant difference in rate from control rats at any dose. Plasma levels of haloperidol with these doses were in the human therapeutic range; with clozapine only the highest dose produced plasma levels in the human therapeutic range. These data show little association between rat oral dyskinesias and clozapine treatment, whereas a strong association is present with haloperidol. The data are, thereby, consistent with the clinical association of tardive dyskinesia with typical neuroleptics like haloperidol but not with the atypical neuroleptic clozapine.

KW - Chronic clozapine

KW - Chronic haloperidol

KW - Dose-response

KW - Oral dyskinesias

KW - Tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=0031026006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031026006&partnerID=8YFLogxK

U2 - 10.1007/BF01271298

DO - 10.1007/BF01271298

M3 - Article

VL - 104

SP - 97

EP - 104

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 1

ER -